1Danthinne X, Imperiale M J. Production of first generation adenovirus vector.. A Review [ J]. Gene Ther,2000, 7..1 707-1 714.
2Lusky M,Christ M,Rittner K, et al. In Vitro and in Vivo Biology of Recombinant Adenovirus Vec- tors with El, EI/E2A, orE1/E4 Deleted[J].l. Virol. , 1998, 72:2022-2032.
3Ng P, Parks PJ, Cummings DT, et al. A high—ef- ficiency Cre/loxP— based system for construction of adenoviral vectors[J]. Hum Gene Ther, 1999, 10:2 667-2 672.
4Scaglioni P, Melegari M,Takahashi M, et al. Use of dominant neative mutants o~ the hepadnaviral core protein as antiviral agents[J]. Hepatology, 1996, ~4:1010-1017.
5Qin X, Tao N, Dergay A, et al. Interferon—~gene therapy inhibits tumor formation and causes regres- sion of established tumors in immune- deficient mice[J]. Proc Natl Acad Sci USA, 1998,95 (24): 14 411-14 416.
6Putzer B M, Stiewe T, Rodicker F, et al. Large nontransplanted hepatocellular carcinoma in wood- chucks ~ treatment with adenovirus— mediated deliv- ery of interleukin 12/B7. 1 genes[J]. Natl Cancer Inst,2001,93(6) :472-479.
7Gao M H, Lai N C, McKirnan M D, et al.. In- creased regional function and perfusion after intra- coronary delivery of adenovirus encoding fibroblast growth factor 4.. Report of preclinical data [J]. Hum Gene Ther, 2004,15 .. 574-587.
8Masahiro U, Fuminori S, Tomoko Y, et al. Pre- vention of hepatic ischemia—reperfusion injury by pre—administration of eatalase—expressing adeno- virus vectors [J]. Journal of Controlled Release, 2010,142:431-437.
同被引文献38
1陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
2Buchholz PM, Buchholz AP, Augustin AJ. Antivascular endothelial growth factor as an approach for macular edema [ J ]. Dev Ophthalmo1,2010,46 ( 1 ) : 111 - 112.
3Bazan-Peregrino M, Seymour LW, Harris AL. Gene therapy targeting to tumor endothelium [ J]. Cancer Gene Ther,2007,14 (2) :117 -127.
4Obeid M, Tesniere A, GhiringheUi F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death [ J ]. Nat Med, 2007,13(1) :54 -61.
5Dreieicher E, Beck KF, Lazaroski S, et al. Nitric oxide inhibits glomerilar TGF-β singaling via SMOC-1 [ J]. J Am Soc Nephrol, 2009,20 (9) : 1963 - 1974.
6Choi YA, Lim J, Kim KM, et al. Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation [ J ]. J Proteome Res, 2010,9 ( 6 ) : 2946 - 2956.
7Brcllier F, Ruggiero S ,Zwolanek D,et al. SMOC1 is a tenascin-C interacting protein over-expressed in brain tumors [ J ]. Matrix Biol,2011,30 ( 3 ) :225 - 233.
8Chen CR, Aliesky H, Pichurin PN, et al.Susceptibility rath resistance to hyperthyroidism is dominant in a thyrotrepin reeept ade-- novirus-indueed animal model of Graves' disease as revealed 1/13AI.,B/e -C57BL/6 hybrid mice[J].Endoerinology, 2004,145(11) :4927-4933, 11.
9Pichurin PN, Chen CR, Chazenbalk GD, et al.T expression of the human thyrotropin receptor A-subunit to the mouse thyroid: in- sight into overcoming the lack of response to A-subunit adenovirus im- munization[J].J Immunol, 2006, 176( 1 ) : 668-676.
10Ye F, Hou P, Wu X, et al.The significance of immune-related molecule expression profiles in an animal model of Graves' disease[J].Au- toimmunitv.2012,45(2) : 143-152.
